BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IDE-161 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IDE-161\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07174583-2533@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:IDE-161: Phase 1/2 readout est. (NCT07174583)
DESCRIPTION:IDE-161\, phase 1/2.\nStudy: A Study of IDE849 in Patients With
  DLL3 Expressing Tumors Including Small Cell Lung Cancer\nEstimated primar
 y completion: July 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ide-161#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07174583
URL:https://assetmemo.bio/drug/ide-161#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
